The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis (NCT05806021)
The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis: a Non-inferiority Randomized Controlled Double-blind Study
🩺 Plain-English Summary (8th-Grade Level)
Osteoarthritis of the knee is a common problem that is increasing in prevalence as the population ages. In a knee with osteoarthritis, there is variable damage to the articular cartilage and underlying bone that can cause varying degrees of pain. When pain is bothersome, osteoarthritis is treated to improve functional abilities. One of the most recognized and used treatments is intra-articular cortisone injection. Cortisone is a powerful anti-inflammatory drug that is used to reduce pain. Unfortunately, cortisone can have significant side effects, even when injected locally. The frequency and intensity of these side effects depend largely on the total dose injected. The main side effects include increased blood sugar levels, increased blood pressure and a temporary decrease in the secretion of the stress hormone, cortisol. In the long term, a decrease in articular cartilage thickness in the injected join and overall bone density reduction is also reported. Despite many years of routine use, the smallest effective dose of cortisone injected into the knee joint is unknown. The main objective of the study is to determine the impact on pain and function of different doses of cortisone injected into the knee. The cortisone chosen for this study is triamcinolone acetonide (TA).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (13 items).
Location: Centre Hospitalier Universitaire de Montréal - Hôtel-Dieu — Montreal, Quebec
Age range: 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Bilateral symptomatic primary gonarthrosis
- Grade 4 Kellgren-Lawrence femorotibial osteoarthritis
- Isolated patellofemoral osteoarthritis
- Intra-articular corticosteroid infiltration to the knee within the past 3 months or chronic use of per os corticosteroid
- Intra-articular hyaluronic acid infiltration within the past 12 months.
- Intra-articular infiltration of platelet-rich plasma within the past 12 months.
- Disease affecting the study joint (systemic inflammatory disease, history of septic arthritis, osteonecrosis, etc.).
- Suspicion or presence of active local infectious process.
- Presence or suspicion of local neoplasia or metastasis
- Recent severe trauma to the knee (≤ 3 months)
- Significant cognitive impairment or inadequate language proficiency not allowing adequate response to study questionnaires
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Centre Hospitalier Universitaire de Montréal - Hôtel-Dieu — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (514) 890-8000
Email: dh.luong79@gmail.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Primary Gonarthrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.